Sandoz completes acquisition of EBEWE Pharma, improving global
patient access to affordable injectab
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ * Acquisition of EBEWE Pharma provides strong platform for future growth of differentiated generics business * New global center of excellence for injectable cancer medicines broadens portfolio of affordable medicines for patients * Sandoz to focus on quick and seamless integration for customers and employeesHolzkirchen, September 24, 2009 - Sandoz announced today that it hascompleted its USD 1.3 billion acquisition of EBEWE Pharma's specialtygeneric injectables business, paving the way for the creation of aglobal center of excellence in generic oncology injectables."We are delighted to combine EBEWE Pharma's portfolio and pipeline ofhigh-quality injectables with our global leadership inbiopharmaceuticals, anti-infectives and other innovativetechnologies," said Sandoz CEO Jeff George. "This will greatlyenhance the range of affordable generic anti-cancer medicines Sandozoffers to patients worldwide."In addition to globalizing Austrian-based EBEWE's operations throughits integration within Sandoz, the world's second largest genericscompany, the transaction offers Sandoz a complementary portfolio ofdifferentiated generics, with more than 15 marketed products and astrong pipeline with several near-term launches.Sandoz and EBEWE Pharma will now focus on implementing their jointintegration plans to deliver a smooth transition for allstakeholders. A new global business unit and center of excellence isbeing created to improve customer service worldwide. The new unitwill be based in Unterach, Austria and led by former EBEWE Pharma CEOFriedrich Hillebrand, who will join the Sandoz Executive Committee.Key priorities for the integration include capitalizing on EBEWEPharma's deep hospital marketing capabilities, strong customerpartnerships, skills in developing differentiated generics, andexpertise in injectables manufacturing. The majority of integrationactivities are expected to be completed shortly.Annual sales of the global generic injectables sector were USD 10-12billion in 2008, according to IMS Health, with injectable oncologymedicines accounting for about 30%. Additionally, injectable oncologymedicines with a total of USD 9 billion in annual sales are expectedto lose patent protection by 2015.DisclaimerThis release contains certain forward-looking statements that can beidentified by terminology such as "platform for future growth," "tofocus on," "paving the way for," "pipeline," "will," "planned,""expected," or similar expressions, or by express or implieddiscussions regarding the potential impact on Novartis and its SandozDivision of the EBEWE acquisition, including express or implieddiscussions regarding potential future sales or earnings of theNovartis Group or its Sandoz Division and any potential synergies,strategic benefits or opportunities as a result of the acquisition.You should not place undue reliance on these statements. Suchforward-looking statements reflect the current views of the Groupregarding future events, and involve known and unknown risks,uncertainties and other factors that may cause actual results to bematerially different from any future results, performance orachievements expressed or implied by such statements. There can be noguarantee that Novartis or its Sandoz Division, will achieve anyparticular future financial results or future growth rates or thatNovartis or Sandoz will be able to realize any potential synergies,strategic benefits or opportunities as a result of the EBEWEacquisition. Neither can there be any guarantees with respect to theimpact of the proposed acquisition on Novartis' credit rating. Inparticular, management's expectations could be affected by, amongother things, uncertainties involved in the development of newgeneric pharmaceutical products; unexpected patent litigationoutcomes; unexpected inabilities to obtain or maintain exclusivityperiods for developed products; unexpected regulatory actions ordelays or government regulation generally; Sandoz' ability tosuccessfully merge the two companies and retain key personnel;competition in general; government, industry, and general publicpricing and other political pressures; the impact that the foregoingfactors could have on the values attributed to the Group's assets andliabilities as recorded in the Group's consolidated balance sheet;and other risks and factors referred to in Novartis AG's current Form20-F on file with the US Securities and Exchange Commission. Shouldone or more of these risks or uncertainties materialize, or shouldunderlying assumptions prove incorrect, actual results may varymaterially from those described herein as anticipated, believed,estimated or expected. Novartis is providing the information in thesematerials as of this date and does not undertake any obligation toupdate any forward-looking statements as a result of new information,future events or otherwise. # # #About SandozSandoz, a Division of the Novartis group, is a global leader in thefield of generic pharmaceuticals, offering a wide array ofhigh-quality, affordable products that are no longer protected bypatents. Sandoz has a portfolio of approximately 1000 compounds andsells its products in more than 130 countries. Key product groupsinclude antibiotics, treatments for central nervous system disorders,gastrointestinal medicines, cardiovascular treatments and hormonetherapies. Sandoz develops, produces and markets these medicinesalong with pharmaceutical and biotechnological active substances andanti-infectives. In addition to strong organic growth in recentyears, Sandoz has made a series of acquisitions including Lek(Slovenia), Sabex (Canada), Hexal (Germany) and Eon Labs (US). In2008, Sandoz employed around 23,000 people worldwide and posted salesof USD 7.6 billion. # # #For further informationCentral media line: +41 61 324 2200Eric Althoff Chris LewisNovartis Global Media Relations Sandoz Global Communications +49 8024 476 2550+41 61 324 7999 chris.lewis(at)sandoz.comeric.althoff(at)novartis.comNovartis Investor RelationsInternational: North America:Ruth Metzler-Arnold Richard Jarvis +1 212 830 2433Pierre-Michel Bringer Jill Pozarek +1 212 830 2445John Gilardi Edwin Valeriano +1 212 830 2456Thomas Hungerbuehler E-mail:Isabella Zinck investor.relations(at)novartis.comCentral phone no: +41 61 3247944E-mail:investor.relations(at)novartis.comhttp://hugin.info/134323/R/1343289/321740.pdf --- End of Message ---Novartis International AGPosfach Basel WKN: 904278; ISIN: CH0012005267; Index: SLCI, SMI, SPI, SLIFE;Listed: Main Market in SIX Swiss Exchange, ZLS in BX Berne eXchange;
Datum: 24.09.2009 - 07:15 Uhr
Sprache: Deutsch
News-ID 6156
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 420 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sandoz completes acquisition of EBEWE Pharma, improving global
patient access to affordable injectab"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
